Q-omics provides the consensus-scored MIR4477B profile across patient tissues and cancer cell-line models. MIR4477B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4477B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MIR4477B RNA expression shows 13,845 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight KIRC, BLCA, and READ as cancer lineages where MIR4477B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4477B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4477B survival associations across molecular data types. MIR4477B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4477B RNA expression–survival associations across cancer types. High MIR4477B expression shows unfavorable associations in KIRC and ACC, but favorable associations in LUSC, BRCA, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4477B RNA expression.
This table summarizes MIR4477B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4477B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4477B shows lower tumor expression in COAD and KICH and higher tumor expression in BLCA, KIRC, HNSC and KIRP. The BLCA box plot shows higher MIR4477B RNA expression in tumor versus normal tissue (log2 FC = +2.885, t-test p < 0.001).
This table shows molecular features associated with MIR4477B in patient tissues and cancer cell lines. In patient samples, MIR4477B shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
